Correlation Between Cell Source and ACRO Biomedical

Can any of the company-specific risk be diversified away by investing in both Cell Source and ACRO Biomedical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cell Source and ACRO Biomedical into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cell Source and ACRO Biomedical Co, you can compare the effects of market volatilities on Cell Source and ACRO Biomedical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cell Source with a short position of ACRO Biomedical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cell Source and ACRO Biomedical.

Diversification Opportunities for Cell Source and ACRO Biomedical

-0.5

Correlation Coefficient

Cell Source  ACRO Biomedical

Very good diversification

The 3 months correlation between Cell and ACRO is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Cell Source and ACRO Biomedical Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ACRO Biomedical and Cell Source is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cell Source are associated (or correlated) with ACRO Biomedical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ACRO Biomedical has no effect on the direction of Cell Source i.e., Cell Source and ACRO Biomedical go up and down completely randomly.

Pair Corralation between Cell Source and ACRO Biomedical

Given the investment horizon of 90 days Cell Source is expected to generate 2.7 times more return on investment than ACRO Biomedical. However, Cell Source is 2.7 times more volatile than ACRO Biomedical Co. It trades about 0.09 of its potential returns per unit of risk. ACRO Biomedical Co is currently generating about -0.13 per unit of risk. If you would invest  26.00  in Cell Source on May 15, 2025 and sell it today you would earn a total of  9.00  from holding Cell Source or generate 34.62% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	98.39%
Values	Daily Returns

Cell Source  vs.  ACRO Biomedical Co

Cell Source

Risk-Adjusted Performance

Fair

Compared to the overall equity markets, risk-adjusted returns on investments in Cell Source are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental indicators, Cell Source unveiled solid returns over the last few months and may actually be approaching a breakup point.

ACRO Biomedical

Risk-Adjusted Performance

Weakest

Over the last 90 days ACRO Biomedical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in September 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Cell Source and ACRO Biomedical

The main advantage of trading using opposite Cell Source and ACRO Biomedical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cell Source position performs unexpectedly, ACRO Biomedical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACRO Biomedical will offset losses from the drop in ACRO Biomedical's long position.

The idea behind Cell Source and ACRO Biomedical Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.